Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.
作者信息
MacDermot K D, Holmes A, Miners A H
出版信息
J Med Genet. 2001 Nov;38(11):769-75. doi: 10.1136/jmg.38.11.769.
Abstract
摘要
相似文献
1
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.
J Med Genet. 2001 Nov;38(11):769-75. doi: 10.1136/jmg.38.11.769.
2
Natural history of Fabry disease in affected males and obligate carrier females.
J Inherit Metab Dis. 2001;24 Suppl 2:13-4; discussion 11-2. doi: 10.1023/a:1012447102358.
3
Renal involvement in an Anderson-Fabry heterozygote.
Postgrad Med J. 2002 Dec;78(926):759. doi: 10.1136/pmj.78.926.759.
4
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.
J Med Genet. 2001 Nov;38(11):750-60. doi: 10.1136/jmg.38.11.750.
5
Isolated cardiac manifestations in Fabry disease: the UK experience.
Acta Paediatr Suppl. 2002;91(439):28-30. doi: 10.1111/j.1651-2227.2002.tb03106.x.
6
[Anderson-Fabry disease. Current status. Apropos of a case].
Med Cutan Ibero Lat Am. 1987;15(2):123-34.
7
Clinical and genetic analysis of Fabry disease: report of six cases including three heterozygous females.
J Dermatol Sci. 2008 Oct;52(1):61-4. doi: 10.1016/j.jdermsci.2008.04.009. Epub 2008 Jun 13.
8
A case of multiple angiomas without any angiokeratomas in a female heterozygote with Fabry disease.
Australas J Dermatol. 2010 Feb;51(1):36-8. doi: 10.1111/j.1440-0960.2009.00590.x.
9
Simultaneous multicystic kidney and Anderson-Fabry disease: 2 separate entities or same side of the coin.
J Nephrol. 2011 Nov-Dec;24(6):806-8. doi: 10.5301/jn.5000031.
10
The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
J Inherit Metab Dis. 2007 Feb;30(1):68-78. doi: 10.1007/s10545-006-0484-8. Epub 2007 Jan 5.
引用本文的文献
1
Fabry disease in females: organ involvement and clinical outcomes compared with the general population (103/150 characters).
Orphanet J Rare Dis. 2025 Aug 13;20(1):433. doi: 10.1186/s13023-025-03922-x.
2
Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.
J Clin Med. 2025 Jul 18;14(14):5131. doi: 10.3390/jcm14145131.
3
Cardiac magnetic resonance imaging in Fabry disease.
J Clin Imaging Sci. 2025 Jun 25;15:23. doi: 10.25259/JCIS_155_2024. eCollection 2025.
4
Multidisciplinary Care Model as a Center of Excellence for Fabry Disease: A Practical Guide to Diagnosis and Management by Clinical Specialty in South Korea.
J Clin Med. 2025 Jun 20;14(13):4400. doi: 10.3390/jcm14134400.
5
A Retrospective Cohort Study of the GLA c.937G > T, p.Asp313Tyr Variant With No Evidence of an Association With Fabry Disease.
Neurol Genet. 2025 Jun 25;11(4):e200271. doi: 10.1212/NXG.0000000000200271. eCollection 2025 Aug.
6
Characterizing pain in patients with Fabry disease: findings from a web-based cross-sectional survey in the US.
Orphanet J Rare Dis. 2025 Jun 16;20(1):308. doi: 10.1186/s13023-025-03812-2.
7
Exploring the burdens of women living with Fabry disease in Japan: A patient survey of 62 respondents.
Mol Genet Metab Rep. 2025 May 30;43:101231. doi: 10.1016/j.ymgmr.2025.101231. eCollection 2025 Jun.
8
Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.
Mol Genet Metab Rep. 2025 Apr 11;43:101215. doi: 10.1016/j.ymgmr.2025.101215. eCollection 2025 Jun.
9
MRI T2 Mapping of Dorsal Root Ganglia Reveals Increased T2 Relaxation Time in Classical Fabry Disease.
Biomedicines. 2025 Feb 28;13(3):592. doi: 10.3390/biomedicines13030592.
10
Cutaneous manifestations of Fabry disease: A systematic review.
J Dermatol. 2025 Apr;52(4):571-582. doi: 10.1111/1346-8138.17690. Epub 2025 Mar 7.
Zotero 插件